(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Latvia seeks emergency UN meeting over Russian missile attack on Lviv - 2Iranian strikes on Israel injure 11 and set chemical plant ablaze
- 37 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- 4Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- 5The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
- The Best Design Bloggers for Style Motivation
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- Eleven Creations And Developments That Steered History
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
